Once launched, Harvoni is expected to quickly supplant Sovaldi as the standard of care for the treatment of hepatitis C patients.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
If confirmed later this year, the $502 price for Cologuard is a big win for Exact Sciences because it means Medicare gave the company everything asked for during reimbursement negotiations.
CEOs of early stage biotech companies like Arrowhead cannot deliver nasty surprises to Wall Street, yet some inexplicable reason, Anzalone totally botched the job.
Tekmira shares surge after Thomas Duncan's death announced.
In an ongoing phase II study, ARC-520 dosed at 2 mg/kg induced a 0.3 log reduction in HBsAG, a measure of the presence of hepatitis B virus in the body.
If Northwest Bio's cancer vaccines -- DCVax-L and DCVax Direct -- are so promising, hedge funds should be falling over themselves to own the stock, not short it.
For the past three months, small-cap biotech stocks have been underperforming the broader market.
Treatment with an experimental formulation of vitamin B6 known as MDX failed to improve the symptoms of attention-deficit hyperactivity disorder compared to placebo.
Sunesis' experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.